参考文献
2020-10-20
1: Vaswani RG, Gehling VS, Dakin LA, Cook A, Nasveschuk CG, Duplessis M, Iyer P,
Balasubramanian S, Zhao F, Good AC, Campbell R, Lee C, Cantone N, Cummings RT,
Normant E, Bellon SF, Albrecht BK, Harmange JP, Trojer P, Audia JE, Zhang Y,
Justin N, Chen S, Wilson J, Gamblin S. Identification of
(R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1
-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205),
a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for
Phase I Clinical Trials for B-Cell Lymphomas. J Med Chem. 2016 Oct 14. PubMed
PMID: 27739677.
Balasubramanian S, Zhao F, Good AC, Campbell R, Lee C, Cantone N, Cummings RT,
Normant E, Bellon SF, Albrecht BK, Harmange JP, Trojer P, Audia JE, Zhang Y,
Justin N, Chen S, Wilson J, Gamblin S. Identification of
(R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1
-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205),
a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for
Phase I Clinical Trials for B-Cell Lymphomas. J Med Chem. 2016 Oct 14. PubMed
PMID: 27739677.
